Amyloid blood biomarker detects Alzheimer's disease

Research output: Contribution to journalArticle


Alzheimer's disease (AD) is currently incurable, but there is general agreement that a minimally invasive blood biomarker for screening in preclinical stages would be crucial for future therapy. Diagnostic tools for detection of AD are either invasive like cerebrospinal fluid (CSF) biomarkers or expensive such as positron emission tomography (PET) scanning. Here, we determine the secondary structure change of amyloid-β (Aβ) in human blood. This change used as blood amyloid biomarker indicates prodromal AD and correlates with CSF AD biomarkers and amyloid PET imaging in the cross-sectional BioFINDER cohort. In a further population-based longitudinal cohort (ESTHER), the blood biomarker detected AD several years before clinical diagnosis in baseline samples with a positive likelihood ratio of 7.9; that is, those who were diagnosed with AD over the years were 7.9 times more likely to test positive. This assay may open avenues for blood screening of early AD stages as a funnel for further more invasive and expensive tests.


  • Andreas Nabers
  • Laura Perna
  • Julia Lange
  • Ute Mons
  • Jonas Schartner
  • Jörn Güldenhaupt
  • Kai Uwe Saum
  • Shorena Janelidze
  • Bernd Holleczek
  • Dan Rujescu
  • Oskar Hansson
  • Klaus Gerwert
  • Hermann Brenner
External organisations
  • Ruhr-University Bochum
  • German Cancer Research Centre
  • Martin-Luther-Universität Halle-Wittenberg
  • Heidelberg University
  • Saarland Cancer Registry
  • Skåne University Hospital
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Biomedical Laboratory Science/Technology


  • Alzheimer's disease diagnosis, Amyloid-β in blood plasma, BioFINDER, ESTHER, Immuno-infrared-sensor
Original languageEnglish
Article numbere8763
JournalEMBO Molecular Medicine
Issue number5
Early online date2018 Jan 1
Publication statusPublished - 2018
Publication categoryResearch